Supporting patients in the transition to the revised pexidartinib dosing regimen: perspectives from the multidisciplinary clinical and allied health professional team

Supporting patients in the transition to the revised pexidartinib dosing regimen: perspectives from the multidisciplinary clinical and allied health professional team

Abstract Pexidartinib is a colony-stimulating factor-1 receptor inhibitor approved in the United States for treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery. Becau...

Full description

Bibliographic Details
Main Authors: Colleen McCabe, Hillary Wright, Kathleen Polson, Andrew J. Wagner
Format: Article
Language:English
Published: BMC 2023-10-01
Series:Orphanet Journal of Rare Diseases
Subjects:
Pexidartinib
Label change
Dosing
Dosing regimen
Administration
Fasted
Online Access:https://doi.org/10.1186/s13023-023-02926-9

Internet

https://doi.org/10.1186/s13023-023-02926-9

Similar Items